Germany-based Bayer and Dewpoint Therapeutics, located in Boston, announced a research deal that could hit $100 million. The research pact will leverage Dewpoint’s biomolecular condensates technology platform and Bayer’s small molecule compound library to identify and develop new therapies for cardiovascular and gynecological diseases.
Biomolecular condensates are droplet-like membrane-less organelles that form in a dynamic fashion with many proteins in order to function within cells. About 80% of proteins in humans are considered unreachable with small molecule drugs. The companies believe that with Dewpoint’s platform, they will broaden the reach of small molecule therapeutics, identifying new drug targets.
“As we continue to broaden our capabilities in Research & Development, the collaboration with Dewpoint gives us access to breakthrough innovation potential,” said Joerg Moeller, member of Bayer’s executive committee’s Pharmaceuticals Division and head of Research and Development. “New analytic tools and a growing understanding of biomolecular condensates could provide new insights into cellular functions that previously have not been considered by scientists in drug development, enabling us to identify novel pharmacological targets for future therapies.”
Under the terms of the deal, Bayer picks up an option to exclusively license a specific number of novel therapeutics that come out of the research. In addition to access to Bayer’s small molecule compound library, it brings R&D capabilities including high throughput screening and medicinal chemistry. No other financial details were disclosed. Nor was the length of the pact.
In January 2019, Bayer participated in Dewpoint’s $60 million Series A financing via the Leaps by Bayer investment unit.